Prelude Therapeutics (PRLD) Asset Utilization Ratio (2025 - 2026)

Prelude Therapeutics (PRLD) posted Asset Utilization Ratio of 0.13 for Q1 2026, down 6.29% sequentially from 0.14 in Q4 2025.

Prelude Therapeutics (PRLD) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Prelude Therapeutics has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.13 in Q1 2026.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.13 (changed N/A YoY) and the FY2025 annual result came in at 0.08, up 148.06% from the prior year.
Asset Utilization Ratio slipped to 0.13 in Q1 2026 per PRLD's latest filing, from 0.14 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.14 in Q4 2025 and troughed at 0.13 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.38
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.69
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	186.67
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.13
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.90
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.54
10	Prelude Therapeutics	442.91 Mn	162.28 Mn	-	0.15

Download Data